Henri Termeer
About
Henri A. Termeer (born 28 February 1946) is an American biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" including Verastem, Inc. He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Key details
| Born | |
| Died |
(aged )
|
| Zodiac | |
| Tags | Add tag |
Family members
Romantic interests
Friends & associates
Scholars
Missing information for Henri Termeer
- missing gender
- missing date of birth
- missing nationality
- missing occupation
- missing height
- missing hair color
- missing eye color
- missing ethnicity
- add banner photo
- add photos to gallery
Similar profiles
Activity
Top contributors today
Tags
Featured contributors
Couples by country
USA · UK · Canada · Australia · France · Germany · India · China · South Korea · Japan · Spain · MexicoCouples by decade
1900s · 1910s · 1920s · 1930s · 1940s · 1950s · 1960s · 1970s · 1980s · 1990s · 2000s · 2010s · 2020s
